Enfortumab Vedotin With or Without Pembrolizumab in Metastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis.

JAMA Netw Open · 2025 · PMC11897842 · PMID 40067303

Europe PMC DOI

hedged sentence

0.0600

closest p · 1.2× alpha

0.0600

boldest claim

The sentences

did not reach statistical significanceP = .06so close (0.05 < p ≤ 0.1)

Regarding ORR, enfortumab vedotin plus pembrolizumab was associated with higher rates compared with chemotherapy (OR, 3.47; 95% CI, 1.49-8.09; P = .004), whereas the comparison between enfortumab vedotin monotherapy and chemotherapy for ORR did not reach statistical significance (OR, 2.29; 95% CI, 0.97-5.42; P = .06) ( Figure 4 B).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.